Loading stock data…
PHGE
$0.79-0.06 (-7.11%)
Market ClosedLast close May 1
BiomX Inc., a clinical-stage biopharmaceutical company, develops phage-based therapies using natural and engineered phage technologies designed to target and kill specific harmful bacteria associated with chronic diseases.
Historical Price
Price (Candle)
50-Day SMA
200-Day SMA
Whystock Brain
The Narrative
BiomX Inc. in the Healthcare sector is trading at $0.79. The stock is currently near its 52-week low of $0.62, remaining 87.5% below its 200-day moving average. Technical signals show oversold RSI of 11 and bearish MACD signal, explaining why PHGE maintains its current current market pressure. The Whystock Score of 25/100 signals elevated caution as indicators diverge.
Ecosystem Influences
Oversold momentum (RSI 11) — potential for technical mean-reversion
Long-term trend bearish (Price vs 200-day SMA)
Macro-economic sensitivity to interest rate and inflation shifts
Loading Financials...
Peer Comparison
JNJUNHPFE
Whystock Valuation Model
Whystock fair value is estimated using a trailing P/E model adjusted for return on equity: Fair P/E = 18 + (ROE × 20). Fair Value = (Current Price ÷ Trailing P/E) × Fair P/E. A base P/E of 18 represents a typical market multiple, scaled upward for companies that earn high returns on equity. The result is a theoretical "normalised" price — not a price target or investment advice. Large deviations are common for high-growth or loss-making companies.
Current Price$0.79
Potential Upside
5%
Whystock Fair Value$0.83
Price
UndervaluedFair ValueOvervalued
Simplified model based on P/E and ROE. Not a substitute for full valuation analysis. Data may be delayed. See our Terms.
Analyst Consensus1 analysts
Mean target$304.00+38400.5%
Range$304.00 – $304.00
Fundamentals
BiomX Inc., a clinical-stage biopharmaceutical company, develops phage-based therapies using natural and engineered phage technologies designed to target and kill specific harmful bacteria associated with chronic diseases. The company's phage-based t...
Market Cap
Total dollar market value of a company's outstanding shares of stock (Price * Shares).
$9.73M
P/E Ratio
Priced for growth. Investors expect sustained double-digit expansion.
-
Beta
High-beta play. Expect amplified moves vs. the broad market.
1.70
Div Yield
Low to zero yield. Return is entirely dependent on price appreciation.
0.00%
ROE
Average efficiency. Growth may require heavy reinvestment.
-356.43%
Volume
Today's trading volume
507,727
Recent News
Johnson & Johnson Exits 3 Biotechs but Keeps Stakes in These Rumored Acquisition Targets
Johnson & Johnson’s restated fourth-quarter holdings report, filed last week, reveals that the company exited three biotechs while retaining its stakes in several rumored acquisition targets. The changes included the sale of 247,598 shares in Arrowhead Pharmaceuticals previously a partner of Johnson & Johnson’s Janssen unit, which rebranded as its Innovative Medicine division. Johnson & Johnson also exited BiomX another former collaborator, through the sale of 96,866 shares.
BiomX announces $3M private placement
BiomX (PHGE) entered into definitive agreements in connection with a private investment in public equity financing for expected gross proceeds of approximately $3M, before deducting placement agent fees and other offering expenses. H.C. Wainwright & Co. acted as the exclusive placement agent for the private placement. In the Private Placement, the Company agreed to issue and sell shares of its Series Y Convertible Preferred Stock, with a stated value of $1,000 per share, together with warrants w
All You Need to Know About BiomX (PHGE) Rating Upgrade to Buy
BiomX (PHGE) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.
Sector Update: Health Care Stocks Fall Late Afternoon
Health care stocks declined late Monday afternoon, with the NYSE Health Care Index down 1.1% and the
Top Midday Decliners
Meihua International Medical Technologies (MHUA) shares plunged 43% after the company reported late